| A Phase II randomized trial of bicalutamide among patients receiving intravesical induction BCG for non-muscle invasive bladder cancer |
Bladder cancer, the second most common urological cancer after prostate cancer, is often treated by intravesical instillation of bacillus Calmette-Guérin (BCG). However, a significant percentage of patients experience relapses or disease progression. This study aims to evaluate the effectiveness of daily addition of bicalutamide to BCG instillation in reducing the recurrence rate of non-muscle-invasive bladder cancer. Health Canada has authorized this combination of treatments on an experimental basis.
Stade de la Maladie: Précoce
Organe: Vessie
Maladie: Cancer de la vessie
